Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05084508 · ClinicalTrials.gov registry record · Phase 2
A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 800
- Enrollment target
NCT05084508: Completed Phase 2 study, sponsored by GlaxoSmithKline.
NCT05084508 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 800 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (502% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05084508, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 800 participants
- Enrollment target
Study Summary
The purpose of this study is to assess immune response and safety of various potencies of an investigational chickenpox vaccine given to healthy children 12 to 15 months of age.
Primary Outcome
Concentrations of anti-VZV gE antibodies were presented as Geometric Mean Concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL) for each group.
Interventions
- BIOLOGICAL Investigational varicella vaccine low potency
- BIOLOGICAL Investigational varicella vaccine medium potency
- BIOLOGICAL Investigational varicella vaccine high potency
- BIOLOGICAL Licensed varicella vaccine Lot 1
- BIOLOGICAL Licensed varicella vaccine Lot 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2022-02-03 |
| Est. Completion | 2024-06-13 |
| Phase | Phase 2 |
What the finished NCT05084508 record still lists
NCT05084508 is an interventional study that assigns participants to a tested intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (502% higher).
The record links to 0 conditions, and to 5 interventions - of which Investigational varicella vaccine low potency is the first listed.
NCT05084508 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05084508 about?
NCT05084508 is a clinical study titled "A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age". The purpose of this study is to assess immune response and safety of various potencies of an investigational chickenpox vaccine given to healthy children 12 to 15 months of age.
What is the current status of trial NCT05084508?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 800 participants. The study started on 2022-02-03. Estimated completion is 2024-06-13.
What interventions are being tested in trial NCT05084508?
The interventions under investigation include: Investigational varicella vaccine low potency (BIOLOGICAL), Investigational varicella vaccine medium potency (BIOLOGICAL), Investigational varicella vaccine high potency (BIOLOGICAL), Licensed varicella vaccine Lot 1 (BIOLOGICAL), Licensed varicella vaccine Lot 2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05084508?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05084508's enrollment target sits among peer trials
800 37th of 2000 higher than 1,961 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00695214 · 800 participants · Phase 2
Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea
- NCT03048201 · 800 participants · NA
Physica System Total Knee Replacement Registry Study
- NCT03792659 · 800 participants
The EXPLORE MG Registry for Myasthenia Gravis
- NCT03819296 · 800 participants · Phase 1
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI